Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Jefferies Group boosted their Q4 2017 earnings per share estimates for Bio-Rad Laboratories in a report issued on Monday. Jefferies Group analyst B. Couillard now anticipates that the medical research company will post earnings per share of $1.74 for the quarter, up from their prior estimate of $1.62. Jefferies Group has a “Buy” rating and a $275.00 price target on the stock. Jefferies Group also issued estimates for Bio-Rad Laboratories’ Q4 2018 earnings at $1.34 EPS.
ILLEGAL ACTIVITY WARNING: “Jefferies Group Analysts Raise Earnings Estimates for Bio-Rad Laboratories, Inc. (BIO)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://stocknewstimes.com/2017/10/11/jefferies-group-analysts-raise-earnings-estimates-for-bio-rad-laboratories-inc-bio.html.
A number of other research analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Deutsche Bank AG reissued a “buy” rating and set a $255.00 target price on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price for the company. Finally, BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $240.00.
Bio-Rad Laboratories (NYSE:BIO) opened at 222.67 on Tuesday. The firm has a market cap of $6.60 billion, a price-to-earnings ratio of 440.06 and a beta of 0.91. The company’s 50-day moving average price is $222.12 and its 200-day moving average price is $220.81. Bio-Rad Laboratories has a 52-week low of $154.89 and a 52-week high of $242.79.
In other news, EVP Michael Crowley sold 700 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the transaction, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.29% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the company. USA Financial Portformulas Corp bought a new position in shares of Bio-Rad Laboratories during the 2nd quarter valued at approximately $782,000. Dynamic Technology Lab Private Ltd boosted its holdings in Bio-Rad Laboratories by 20.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 1,618 shares of the medical research company’s stock worth $366,000 after buying an additional 272 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Bio-Rad Laboratories by 1.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,229 shares of the medical research company’s stock worth $1,410,000 after buying an additional 100 shares during the period. Martin & Co. Inc. TN boosted its holdings in Bio-Rad Laboratories by 0.6% in the 2nd quarter. Martin & Co. Inc. TN now owns 6,825 shares of the medical research company’s stock worth $1,545,000 after buying an additional 40 shares during the period. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in Bio-Rad Laboratories by 1.2% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 6,364 shares of the medical research company’s stock worth $1,440,000 after buying an additional 78 shares during the period. 62.84% of the stock is owned by hedge funds and other institutional investors.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.